Pancreatic Cancer Market

• Pancreatic cancer is one of the most lethal cancers throughout the globe and majorly affects men compared to women. Pancreatic cancer types can be divided into two larger categories: exocrine pancreatic cancer, which includes adenocarcinoma, and neuroendocrine pancreatic cancer.
• The United States accounts for the largest market size (around 50%) of pancreatic cancer, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• Among the approved therapies, LYNPARZA (olaparib) is expected to garner the highest market share in the United States.
• For pancreatic cancer patients showing BRCA mutations, LYNPARZA (olaparib) was approved by the US FDA in 2019. VITRAKVI (larotrectinib) and ROZLYTREK (entrectinib) are approved for solid tumor patients having NTRK gene expression. Other than these, KEYTRUDA (pembrolizumab) is approved for solid tumor patients having microsatellite instability-high expression.
• In January 2024, Alligator Bioscience announced positive top-line results from the OPTIMIZE-1 Phase II study of the company’s lead asset mitazalimab in first line metastatic pancreatic cancer.
• The study achieved its primary endpoint demonstrating a confirmed objective response rate (ORR) of 40.4%, an unconfirmed ORR of 50.9% and a disease control rate (DCR) of 79% in 57 evaluable patients, as per the response evaluation criteria in solid tumors.
• The development pipeline for pancreatic cancer is robust, with significant involvement from key players like Alligator Bioscience, Actuate Therapeutics, and other companies advancing into mid-stage clinical trials.

Request for unlocking the CAGR of the Pancreatic Cancer Drugs Market

DelveInsight's “Pancreatic Cancer Market Insights, Epidemiology and Market Forecast – 2036” report delivers an in-depth understanding of pancreatic cancer, historical and forecasted epidemiology as well as the pancreatic cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Pancreatic cancer market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM pancreatic cancer market size from 2022 to 2036. The report also covers current pancreatic cancer treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Explore More Insights of this Report @ LYNPARZA Market

Key Factors Driving the Growth of the Pancreatic Cancer Market 

Rising Pancreatic Cancer Incidence 

According to DelveInsight’s analysis, the total number of incident cases of pancreatic cancer in the US was approximately ~63,700 in 2025.

Role of Immune Checkpoint Inhibitors in PDAC

The potential of immune checkpoint inhibitors, such as anti-PD-1/PD-L1 therapies, is being explored in PDAC. Clinical trials combining immunotherapy with other treatment modalities (e.g., chemotherapy, radiation, or targeted therapies) may increase efficacy and open new treatment pathways.

Advancing Precision Medicine for Pancreatic Cancer

Novel strategies, including RAS-directed therapies and advanced immunotherapies, are being developed to more effectively tackle pancreatic cancer. These approaches offer hope for improved survival and quality of life by targeting cancer more precisely.

Advancing PDAC Treatment Through Targeted and Combination Approaches

The development of new targeted therapies, such as KRAS inhibitors (like Daraxonrasib) or epigenetic modulators, provides an opportunity to treat PDAC based on specific genetic mutations or tumor characteristics. Additionally, combination therapies, which pair existing treatments with newer agents, offer an opportunity to overcome resistance and enhance therapeutic effectiveness.

Emergence of Novel Pancreatic Cancer Drugs

The pancreatic cancer treatment pipeline for metastatic or unresectable pancreatic cancer includes LOAd703 (Lokon Pharma), OT-101 (Oncotelic), Daraxonrasib (Revolution Medicines) (first-line treatment), and Optune (Novocure). In the adjuvant or neoadjuvant setting, therapies under development include Daraxonrasib for resectable PDAC, BNT122 (BioNTech and Genentech), and ELI-002 (Elicio Therapeutics) for patients with high relapse-risk mKRAS+ PDAC.

Emerging KRAS-Targeted Therapies in Pancreatic Cancer

There are multiple KRAS-targeting drugs in development for pancreatic cancer, including HRS-4642 (Jiangsu Hengrui Pharmaceuticals) (with gemcitabine/nab-paclitaxel) for neoadjuvant/adjuvant use, TSN1611 (Tyligand Pharmaceuticals (Suzhou)) for KRAS G12D-mutated tumors, Glecirasib (Jacobio Pharmaceuticals) (JAB-21822) for KRAS G12C-mutated advanced cancers, and others.

Pancreatic Cancer Treatment Market

Pancreatic Cancer Overview, Country-Specific Treatment Guidelines and Diagnosis

Pancreatic cancer begins in the tissues of the pancreas – an organ in the abdomen that lies behind the lower part of the stomach. The pancreas release enzymes that aid digestion and produces hormones that help manage blood sugar. Pancreatic cancer is a disease in which malignant (cancer) cells form in the tissues of the pancreas. Several types of growth can occur in the pancreas, including cancerous and noncancerous tumors. The most common type of cancer that forms in the pancreas begins in the cells that line the ducts that carry digestive enzymes out of the pancreas (pancreatic ductal adenocarcinoma). 

Diagnosing pancreatic cancer involves a medical history review, physical examination, and imaging tests like CT scan, MRI, and endoscopic ultrasound. Biopsy procedures such as fine needle aspiration (FNA) or surgical biopsy confirm cancer presence. Blood tests and additional imaging like PET scan may also be used to assess cancer spread and guide treatment decisions.

The pancreatic cancer report provides an overview of pancreatic cancer pathophysiology, diagnostic approaches, and detailed treatment algorithm along with a real-world scenario of a patient’s journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Further details related to country-based variations in diagnosis are provided in the report

For More Insights @ VITRAKVI Market

Pancreatic Cancer Treatment

About 20% of people diagnosed with pancreatic cancer can have surgery because most pancreatic cancers are found after the disease has already spread. Surgery for pancreatic cancer may be combined with systemic therapy and/or radiation therapy. Typically, these additional treatments are given after surgery, which is called adjuvant therapy. However, systemic therapy and/or radiation therapy may sometimes be used before surgery to shrink a tumor, and this is called neoadjuvant therapy or preoperative therapy.

The chemotherapy drugs used for the treatment of pancreatic cancer include XELODA (capecitabine), 5-FU (fluorouracil), GEMZAR (gemcitabine), CAMPTOSAR (irinotecan), and others.

Targeted therapies such as TARCEVA (erlotinib) was approved by the FDA for people with advanced pancreatic cancer in combination with the chemotherapy drug gemcitabine. Another drug, LYNPARZA (olaparib) is approved for people with metastatic pancreatic cancer associated with a germline (hereditary) BRCA mutation. 

Read More Insights of this report @ ROZLYTREK Market

Pancreatic Cancer Epidemiology

The pancreatic cancer epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2026 to 2036. The pancreatic cancer epidemiology is segmented with detailed insights into Total Incident Cases, Molecular Alteration-specific, and Stage-specific Cases of Pancreatic Cancer.

• As per DelveInsight estimates, exocrine pancreatic cancer is more common than the neuroendocrine pancreatic cancer accounting for more than 90% of total cases. 
• According to DelveInsight’s analysis, the total number of incident cases of pancreatic cancer in the US was approximately ~63,700 in 2025.
• According to the analysis, in the US, the majority of pancreatic cancer cases in 2025 were diagnosed at a distant stage (50%), followed by regional (37%) and localized stages (13%), highlighting a concerning trend of late-stage detection.
  
  
   

Explore the latest insights and forecasts on the Pancreatic Cancer Market to stay ahead in healthcare innovation. Dive into our comprehensive report now @ Pancreatic Cancer Prevalence

Pancreatic Cancer Drug Chapters

The drug chapter segment of the pancreatic cancer report encloses a detailed analysis of pancreatic cancer marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also deep dives into the pancreatic cancer pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations. 

Pancreatic Cancer Marketed Drugs

LYNPARZA (olaparib): AstraZeneca

LYNPARZA (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumors harboring a deficiency in homologous recombination repair, such as mutations in BRCA1 and/or BRCA2. In December 2019, AstraZeneca announced that LYNPARZA (olaparib) had been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

KEYTRUDA (pembrolizumab) is an anti-programmed death receptor-1 (PD-1) therapy that works upon increasing the ability of the body’s immune system to help detect and fight tumor cells. In May 2017, Merck announced that the US FDA had approved KEYTRUDA (pembrolizumab) to treat adult and pediatric patients with unrespectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.

Get More Insights of this report @ KEYTRUDA Market

Note: Detailed marketed therapies assessment will be provided in the final report.

Pancreatic Cancer Emerging Drugs

Daraxonrasib (RMC-6236): Revolution Medicines

Daraxonrasib, a RAS (ON) multi-selective inhibitor, is designed as an oral, RAS-selective tri-complex inhibitor of multiple RAS (ON) variants containing cancer driver mutations at all three of the major RAS mutation hotspot positions. Daraxonrasib inhibits all three major RAS isoforms, suppressing the mutant cancer driver and cooperating wild-type RAS proteins.

The drug is currently being evaluated in the Phase III RASolute-302 trial (NCT06625320) for patients with previously treated metastatic PDAC, with clinical results expected in H1 2026.

Trabedersen (OT-101): Oncotelic

Trabedersen (OT-101) is a first-in-class antisense oligonucleotide targeting TGF-β2 for the treatment of PDAC. By inhibiting TGF-β2 signaling, OT-101 aims to reduce tumor progression and immune evasion while enhancing chemotherapy response. The drug is being evaluated in combination with mFOLFIRINOX for advanced metastatic PDAC.

As per company’s pipeline, the drug is being evaluated in Phase III STOP-PC clinical trial.

Relacorilant (LIFYORLI): Corcept Therapeutics
 
Relacorilant is an investigational selective glucocorticoid receptor antagonist being developed by Corcept Therapeutics for pancreatic cancer. The drug is currently being evaluated in combination with nab-paclitaxel and gemcitabine in a Phase II trial for patients with previously untreated metastatic PDAC, with the aim of enhancing antitumor activity and improving clinical outcomes.

In December 2025, Corcept Therapeutics initiated a Phase II trial, TRIDENT, with a planned enrollment of 60 patients with pancreatic cancer, who have not received prior therapy for metastatic diease. TRIDENT will evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel and gemcitabine,

BNT122 (RO7198457/autogene cevumeran): BioNTech/Genentech

BNT122 is an mRNA cancer vaccine candidate for individualized neoantigen-specific immunotherapy being developed in collaboration with Genentech. It is being evaluated in ongoing Phase II (NCT05968326) trials in combination with atezolizumab followed by standard-of-care chemotherapy (mFOLFIRINOX) in patients with resected adjuvant resected PDAC compared to chemotherapy alone is ongoing. Currently, the drug is being evaluated in Phase II clinical trial. As per company’s 2026 corporate presentation, the data from Phase II final analysis is expected in 2027. 

Note: Detailed emerging therapies assessment will be provided in the final report.

Pancreatic Cancer Recent Developments

• In May 2026, The US Food and Drug Administration (FDA) has issued a “safe to proceed” letter to Revolution Medicines, allowing the company to initiate an expanded access treatment protocol (EAP) for daraxonrasib in patients with previously treated metastatic PDAC.
• In April 2026, Revolution Medicines announced updated Phase I/II data for daraxonrasib in previously untreated metastatic PDAC at the American Association for Cancer Research (AACR) Annual Meeting and revealed that Phase III RASolute 302 trial results in previously treated metastatic PDAC would be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
• In March 2026, Revolution Medicines announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline including daraxonrasib will be featured at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
• In February 2026, Novocure announced that the U.S. Food and Drug Administration (FDA) approved OPTUNE Pax for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.
• In January 2026, ChipScreen Biosciences received regulatory approval from China’s National Medical Products Administration (NMPA) to initiate a new clinical trial for chiauranib in pancreatic cancer, marking a key advancement following encouraging earlier data.
• In October 2025, the US FDA has granted Orphan Drug Designation (ODD) to daraxonrasib, for the treatment of pancreatic cancer.
• In September 2025, Revolution Medicines announced key clinical updates from its Phase I trials of daraxonrasib, supporting the initiation of RASolute-303, a global Phase III registrational study evaluating daraxonrasib as a first-line treatment for metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

Pancreatic Cancer Market Outlook

• DelveInsight estimates that the United States holds the largest market share in 2025 among the 7MM. Chemotherapy regimens remain the dominant standard of care in first-line pancreatic cancer treatment.
• The total market size of pancreatic cancer is expected to increase in the 7MM during the forecast period driven by ongoing clinical research and better diagnostic tools which might improve the prognosis of the disease.

Pancreatic Cancer Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2026–2036, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake. 

Further detailed analysis of emerging therapies drug uptake in the report…

Pancreatic Cancer Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics. 

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for pancreatic cancer emerging therapies. 

Discover how advancements in Pancreatic Cancer therapies are shaping the industry landscape. Gain actionable intelligence from our detailed market report today! @ Pancreatic Cancer Drugs New

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Duke University School of Medicine, Gustave Roussy Institute of Oncology, Heidelberg University Hospital, the University of Texas MD Anderson Cancer Center, etc., were contacted. Their opinion helps understand and validate current and emerging treatment patterns of pancreatic cancer. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. 

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy. 

In efficacy, the trial’s primary and secondary outcome measures are evaluated. One of the most important primary endpoints were overall survival (OS), progression-free survival (PFS), and overall response rate (ORR).

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided. 

Market Access and Reimbursement

LYNPARZA (olaparib)

Medicare covers 100% of medicare prescription drug plans, and in the post-deductible stage, the patient needs to pay their co-pay part, and their plan will cover the rest of the drug cost. The co-pay part which needs to be paid by the patient ranges from USD 28 to USD 129.

KEYTRUDA (pembrolizumab)

Patients with Medicare may or may not have to pay a portion of the cost of KEYTRUDA (pembrolizumab) based on their insurance plan. For example, with a Medicare Advantage plan, 41% of patients had no out-of-pocket costs for the 200 mg dose of KEYTRUDA. Roughly 80% of patients responsible for a portion of the cost paid between USD 0 and USD 925 per infusion after meeting their deductible. Most patients with Medicaid typically pay USD 4–USD 8 per KEYTRUDA infusion. The co-pay part which needs to be paid by the patient ranges from USD 12,045. 

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Pancreatic Cancer Market Report

• The Pancreatic Cancer Therapeutics Market Report covers a segment of key events, an executive summary, a descriptive overview, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along Pancreatic Cancer Treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current Pancreatic Cancer Treatment landscape.
• A detailed review of the Pancreatic Cancer Therapeutics Market, historical and forecasted Pancreatic Cancer Treatment Market Size, Pancreatic Cancer Drugs Market Share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Pancreatic Cancer Therapeutics Market Report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Pancreatic Cancer Drugs Market.

Pancreatic Cancer Market Report Insights

• Pancreatic Cancer Patient Population Forecast
• Pancreatic Cancer Therapeutics Market Size
• Pancreatic Cancer Pipeline Drugs Analysis
• Pancreatic Cancer Market Size and Trends
• Pancreatic Cancer Therapeutics Market Opportunity (Current and Forecasted)

Pancreatic Cancer Market Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI) - enabled Market Research Report
• 11-year forecast
• Pancreatic Cancer Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• Pancreatic Cancer Treatment Addressable Market (TAM)
• Pancreatic Cancer Competitive Landscape
• Pancreatic Cancer Major Companies Insights
• Pancreatic Cancer Price Trends and Analogue Assessment
• Pancreatic Cancer Therapies Drug Adoption/Uptake
• Pancreatic Cancer Therapies Peak Patient Share Analysis

Pancreatic Cancer Market Report Assessment

• Pancreatic Cancer Current Treatment Practices
• Pancreatic Cancer Unmet Needs
• Pancreatic Cancer Clinical Development Analysis
• Pancreatic Cancer Emerging Drugs Product Profiles
• Pancreatic Cancer Market Attractiveness
• Pancreatic Cancer Qualitative Analysis (SWOT and Attribute analysis)

Key Questions Answered in the Pancreatic Cancer Treatment Market Report

Pancreatic Cancer Therapeutics Market Insights

• What was the Pancreatic Cancer Treatment Market Size, the Pancreatic Cancer Market Size by therapies, Pancreatic Cancer Drugs Market Share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Pancreatic Cancer?
• What are the disease risks, burdens, and unmet needs of Pancreatic Cancer? 
• What will be the growth opportunities across the 7MM concerning the patient population with Pancreatic Cancer?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Pancreatic Cancer? What are the current guidelines for treating Pancreatic Cancer in the US, Europe, and Japan?

Reasons to Buy the Pancreatic Cancer Therapeutics Market Report

• The Pancreatic Cancer Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Pancreatic Cancer Drugs Market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease Pancreatic Cancer Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Pancreatic Cancer Drugs Market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the Pancreatic Cancer Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis, ranking of class-wise potential current, and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• To understand KOLs’ perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Pancreatic Cancer Drugs Market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI)   enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Stay Updated with us for new articles:- 

• Ipsen’s Onivyde Combo Ends a Decade-Long Dry Spell in Newly Diagnosed Pancreatic Cancer
• Ipsen’s Cabometyx Rejected by NICE; Vertex and CRISPR Therapeutics’s Submit BLA to the FDA for exa-cel; Orphan Drug Designation to Osemitamab for Pancreatic Cancer; FDA Clears Keytruda/Padcev for Bladder and Urothelial Cancer; Cingulate Completes Trial of CTx-1301 for ADHD; Nuance Pharma Announces Dosing of First Patient in ENHANCE Trial
• Treatment to Clinical Development – A Bumpy Journey for Pancreatic Cancer
• Alcon to acquire Ivantis; Philips to takeover Cardiologs; Flunked cancer drug progresses in I-O in pancreatic cancer models; Indigo system CAT RX catheter meets primary endpoint in trial
• Verily - Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis
• FDA authorizes first diagnostic test for Covid-19 antibodies; EGenesis's collaboration with Duke; Pancreatic Cancer research updates; Decibel scores $ 82 M
• Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust
• J&J collaborates with BARDA; Virus kills pancreatic cancer cells; ALX raises USD 105 million for CD47 drug
• Metastatic Pancreatic Cancer Market Size: Emerging therapies, Unmet needs and Forecast analysis
• Pancreatic Cancer Treatment to Stride Beyond Chemotherapy
• Pancreatic Cancer Market: Infographics

Learn about emerging trends and key players driving the Pancreatic Cancer market. Access our in-depth analysis to strategize for future growth @ Latest DelveInsight Blogs